-
2008
12 February 2008: Press release no. 1, 2008: Phase III program for AVE0010/ZP10 licensed ...
-
Product Pipeline
Pipeline with 1 compound in phase III, 2 compounds in phase II, 3 compounds in phase I and ...
-
Available Positions
We have one vacant position: Scientist-Department of Molecular Pharmacology ...
Rotigaptide
Rotigaptide (Zealand name ZP123) is a novel compound developed with the aim of preventing life threatening ventricular arrhythmia by re-establishing heart tissue conductance and function by modifying gap-junction communication. The compound, which was outlicensed to Wyeth Pharmaceuticals in April 2003, is expected to be the first specific gap-junction modifying drug. Gap-junctions are specialized pores that ensure the coordinated transmission of electrical impulses from cell-to-cell, which is essential for synchronized contraction. This spreading of electrical impulses is scrambled following heart attack (myocardial infarction), which may lead to irregular heart beats, or arrhythmia, followed by cardiac arrest and death. Zealand Pharma has demonstrated in pharmacological models that Rotigaptide/ZP123 specifically inhibits life threatening ventricular arrhythmia, or the so-called re-entry arrhythmias. In the first quarter of 2005, Wyeth completed Phase I clinical trials in which the compound was safe and well-tolerated. In 2007 Wyeth has finalized a global multi-centre Phase IIa safety and tolerability trial in patients with large myocardial infarcts.
Tip a friend
Fill in the form below to tip a friend about this page.
Subscribe
When this page is updated you will be updated by e-mail.